Kurtul, AlparslanDuran, MustafaYarlioglues, MikailMurat, Sani NamikDemircelik, Muhammed BoraErgun, GokhanAcikgoz, Sadik Kadri2025-10-242025-10-2420140160-92891932-8737https://doi.org/10.1002/clc.22291https://hdl.handle.net/20.500.12899/3281Background: Contrast-induced nephropathy (CIN) is associated with significantly increased morbidity and mortality after percutaneous coronary intervention (PCI). Patients with acute coronary syndrome (ACS) are at higher risk for CIN. N-terminal pro-brain natriuretic peptide (NT-proBNP) is closely linked to the prognosis as a strong predictor of both short-and long-term mortality in patients with ACS. Hypothesis: We hypothesized that NT-proBNP levels on admission can predict the development of CIN after PCI for ACS. Methods: A total of 436 patients (age 62.27 +/- 13.01 years; 64.2% male) with ACS undergoing PCI enrolled in this study. Admission NT-proBNP levels were measured before PCI. Serum creatinine values were measured before and within 72 hours after the administration of contrast agents. Patients were divided into 2 groups: CIN group and no-CIN group. CIN was defined as an increase in serum creatinine level of >= 0.5 mg/dL or >= 25% above baseline within 72 hours after contrast administration. Results: CIN developed in 63 patients (14.4%). Baseline NT-proBNP levels were significantly higher in patients who developed CIN compared to those who did not develop CIN (median 774 pg/mL, interquartile range 177.4-2184 vs median 5159 pg/mL, interquartile range 2282-9677, respectively; P < 0.001). Multivariate analysis found that NT-proBNP (odds ratio [OR]: 3.448, 95% confidence interval [CI]: 1.394-8.474, P = 0.007) and baseline creatinine (OR: 6.052, 95% CI: 1.860-19.686, P = 0.003) were independent predictors of CIN. Conclusions: Admission NT-proBNP level is an independent predictor of the development of CIN after PCI in ACS.eninfo:eu-repo/semantics/openAccessAcute Kidney Injury; Acute Myocardial-Infarction; Chronic Heart-Failure; Risk Stratification; Prediction; Disease; Cells; Mortality; Cardiology; CreatinineArticle10.1002/clc.22291378485492248059952-s2.0-84906314821Q2WOS:000340528400006Q2